Literature DB >> 8912560

Redefining the Sjögren-Larsson syndrome: atypical findings in three siblings and implications regarding diagnosis.

J F Nigro1, W B Rizzo, N B Esterly.   

Abstract

BACKGROUND: The Sjögren-Larsson syndrome is a rare condition characterized by ichthyosis, spasticity, and mental retardation. Patients have deficient activity of the aldehyde portion of the fatty alcohol:nicotinamide adenine denucleotide (NAD+) oxidoreductase complex.
OBJECTIVE: Our purpose was to describe atypical findings in three siblings with the Sjögren-Larsson syndrome and implications regarding diagnosis.
METHODS: Medical histories were taken and physical examinations performed on four siblings and their parents. Analysis of fibroblast fatty alcohol:NAD+ oxidoreductase or fatty aldehyde dehydrogenase activity (or of both) was determined in each.
RESULTS: Decreased fibroblast fatty alcohol:NAD+ oxidoreductase or fatty aldehyde dehydrognase levels (or both) were present in three of four siblings. The fourth sibling and the parents had levels similar to obligate heterozygotes. None of the affected siblings fulfilled the classic criteria for the syndrome.
CONCLUSION: Although all affected siblings had abnormally low activity of the fatty alcohol:NAD+ dehydrogenase complex, their clinical findings were variable. This divergence of clinical features in siblings has not been previously reported. We propose that deficient activity of the fatty alcohol:NAD+ dehydrogenase complex be considered part of the definition of the Sjögren-Larsson syndrome that would also include the probable, but not absolute, presence of ichthyosis, mental retardation, and spasticity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912560     DOI: 10.1016/s0190-9622(96)90720-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Novel mutation in Sjogren-Larsson syndrome is associated with divergent neurologic phenotypes.

Authors:  Kathleen Davis; Kenton R Holden; Dana S'Aulis; Claudia Amador; M Gisele Matheus; William B Rizzo
Journal:  J Child Neurol       Date:  2012-10-03       Impact factor: 1.987

2.  Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.

Authors:  William B Rizzo
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-10       Impact factor: 0.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.